A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Status:
Active, not recruiting
Trial end date:
2022-03-21
Target enrollment:
Participant gender:
Summary
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem.
GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and
in CHB participants on stable nucleos(t)ide therapy. This study is intended to evaluate if
treatment with GSK3228836 can achieve sustained virologic response (SVR), that is hepatitis B
virus surface antigen (HBsAg) less than (<) lower limit of quantitation (LLOQ) and HBV
deoxyribonucleic acid (DNA) Phase:
Phase 2